Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.

Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.

As the United States continues to grapple with the opioid epidemic, researchers have developed a new test that can measure pain biomarkers in the blood.

Bristol-Myers Squibb withdrew the U.S. approval application for a combo of the cancer immunotherapy drugs Opdivo and Yervoy.

Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.

Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).

Belgian molecular diagnostics company Biocartis Group entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

Akoya Biosciences Inc., a Telegraph Hill Partners company, acquired PerkinElmer Inc.’s Phenoptics portfolio.

AstraZeneca’s immunotherapy drug Imfinzi was approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.